Welcome to CDC Stacks | Prevention and control of influenza; recommendations of the Advisory Committee on Immunization Practices (ACIP) - 6735 | Stephen B. Thacker CDC Library collection | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Prevention and control of influenza; recommendations of the Advisory Committee on Immunization Practices (ACIP)
Filetype[PDF - 581.55 KB]

  • Corporate Authors:
    United States, Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) ;
  • Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 55, no. RR-10
  • Document Type:
  • Description:
    Introduction -- Primary Changes and Updates in the Recommendations -- Influenza and Its Burden 3 -- Options for Controlling Influenza -- Comparison of LAIV with Inactivated Influenza Vaccine -- Cost-Effectiveness of Influenza Vaccine -- Vaccination Coverage Levels -- -- Recommendations for Using Inactivated and Live, Attenuated Influenza Vaccines -- Target Groups for Vaccination -- Additional Information Regarding Vaccination of Specific Populations -- Inactivated Influenza Vaccine Recommendations -- Live, Attenuated Influenza Vaccine Recommendations -- Recommended Vaccines for Different Age Groups -- Influenza Vaccine Supply and Timing of Annual Influenza Vaccination -- Strategies for Implementing Vaccination Recommendations in Health-Care Settings -- Future Directions for Research and Recommendations Related to Influenza Vaccine -- -- Recommendations for Using Antiviral Agents for Influenza -- Antiviral Agents for Influenza -- Role of Laboratory Diagnosis -- Antiviral Drug-Resistant Strains of Influenza Virus Indications for Use of Antivirals When Susceptibility Exists -- Dosage -- Route -- Pharmacokinetics -- Side Effects and Adverse Reactions -- Use During Pregnancy -- Drug Interactions -- -- Information Regarding the Vaccines for Children Program -- -- Sources of Information Regarding Influenza and Its Surveillance -- -- Reporting of Adverse Events Following Vaccination -- -- Additional Information Regarding Influenza Virus Infection Control Among Specific Populations -- -- References

    "This report updates the 2005 recommendations by the Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccine and antiviral agents (CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2005;54[No. RR-8]:1--44). The 2006 recommendations include new and updated information. Principal changes include 1) recommending vaccination of children aged 24--59 months and their household contacts and out-of-home caregivers against influenza; 2) highlighting the importance of administering 2 doses of influenza vaccine for children aged 6 months--<9 years who were previously unvaccinated; 3) advising health-care providers, those planning organized campaigns, and state and local public health agencies to a) develop plans for expanding outreach and infrastructure to vaccinate more persons than the previous year and b) develop contingency plans for the timing and prioritization of administering influenza vaccine, if the supply of vaccine is delayed and/or reduced; 4) reminding providers that they should routinely offer influenza vaccine to patients throughout the influenza season; 5) recommending that neither amantadine nor rimantadine be used for the treatment or chemoprophylaxis of influenza A in the United States until evidence of susceptibility to these antiviral medications has been re-established among circulating influenza A viruses; and 6) using the 2006--07 trivalent influenza vaccine virus strains: A/New Caledonia/20/1999 (H1N1)-like, A/Wisconsin/67/2005 (H3N2)-like, and B/Malaysia/2506/2004-like antigens. For the A/Wisconsin/67/2005 (H3N2)-like antigen, manufacturers may use the antigenically equivalent A/Hiroshima/52/2005 virus; for the B/Malaysia/2506/2004-like antigen, manufacturers may use the antigenically equivalent B/Ohio/1/2005 virus." - p. 1

  • Supporting Files:
    No Additional Files